Work

A prostate-specific membrane antigen-targeted nanoplatform for synergistic prostate cancer therapy through androgen receptor transcriptional repression and self-reinforcing chemodynamic pathway

Year: 2026
Type: article
Abstract: Androgen receptor (AR) represents a pivotal molecular target in prostate cancer (PCa), rendering hormonal therapy a central role in clinical management. However, limited therapeutic efficacy is frequently observed due to AR overexpression, aberrant splicing, and metabolic reprogramming-mediated drug resistance. Herein, this study constructs MnS-GUL-CB839 (MGC) nanoplatform, which achieves efficient and targeted accumulation in PCa via active-targeting motif Glu-urea-Lys, potently downregulates the expression of AR and its splice variant AR-V7 , and reverses glutamine dependence. In acidic tumor microenvironment, MGC enables sustained release of manganese ions (Mn 2+ ), hydrogen sulfide (H 2 S) and the glutamine metabolism inhibitor CB839. Specifically, Mn 2+ represses transcription of AR and AR-V7 for AR signaling suppression. In parallel, H 2 S elevates intracellular hydrogen peroxide levels via inhibiting the catalytic activity of catalase, CB839 reverses glutamine addiction and diminishes glutathione production through inhibition of the rate-limiting enzyme in glutamine metabolism termed glutaminase 1. H 2 S and CB839 synergistically amplify Mn 2+ -catalyzed Fenton-like reactions, generating abundant hydroxyl radicals. Ultimately, this cascade realizes enhanced chemodynamic therapy (CDT) for ferroptosis and apoptosis induction. In summary, our findings underscore MGC as a promising nanoplatform to integrate AR signaling suppression, metabolic reprogramming and self-enhanced CDT, which establishes a unified therapeutic paradigm for PCa.
Language: English
Open Access status: gold
Estimated APC paid: $2,200
OpenAlex ID: W7236797191
FWCI:
Cites: 70
Cited by:
Related to: 10